4yzm
From Proteopedia
(Difference between revisions)
m (Protected "4yzm" [edit=sysop:move=sysop]) |
|||
| Line 1: | Line 1: | ||
| - | ''' | + | ==Humanized Roco4 bound to LRRK2-In1== |
| + | <StructureSection load='4yzm' size='340' side='right' caption='[[4yzm]], [[Resolution|resolution]] 3.00Å' scene=''> | ||
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[4yzm]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4YZM OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4YZM FirstGlance]. <br> | ||
| + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=4K4:2-[(2-METHOXY-4-{[4-(4-METHYLPIPERAZIN-1-YL)PIPERIDIN-1-YL]CARBONYL}PHENYL)AMINO]-5,11-DIMETHYL-5,11-DIHYDRO-6H-PYRIMIDO[4,5-B][1,4]BENZODIAZEPIN-6-ONE'>4K4</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene></td></tr> | ||
| + | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Non-specific_serine/threonine_protein_kinase Non-specific serine/threonine protein kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.1 2.7.11.1] </span></td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4yzm FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4yzm OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4yzm RCSB], [http://www.ebi.ac.uk/pdbsum/4yzm PDBsum]</span></td></tr> | ||
| + | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Kinase inhibition is considered to be an important therapeutic target for LRRK2 mediated Parkinson's disease (PD). Many LRRK2 kinase inhibitors have been reported but have yet to be optimized in order to qualify as drug candidates for the treatment of the disease. In order to start a structure-function analysis of such inhibitors, we mutated the active site of Dictyostelium Roco4 kinase to resemble LRRK2. Here, we show saturation transfer difference (STD) NMR and the first cocrystal structures of two potent in vitro inhibitors, LRRK2-IN-1 and compound 19, with mutated Roco4. Our data demonstrate that this system can serve as an excellent tool for the structural characterization and optimization of LRRK2 inhibitors using X-ray crystallography and NMR spectroscopy. | ||
| - | + | Structural Characterization of LRRK2 Inhibitors.,Gilsbach BK, Messias AC, Ito G, Sattler M, Alessi DR, Wittinghofer A, Kortholt A J Med Chem. 2015 May 1. PMID:25897865<ref>PMID:25897865</ref> | |
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| - | + | </div> | |
| - | + | == References == | |
| - | [[Category: | + | <references/> |
| - | [[Category: | + | __TOC__ |
| - | [[Category: Gilsbach, B | + | </StructureSection> |
| + | [[Category: Non-specific serine/threonine protein kinase]] | ||
| + | [[Category: Alessi, D R]] | ||
| + | [[Category: Gilsbach, B K]] | ||
[[Category: Ito, G]] | [[Category: Ito, G]] | ||
[[Category: Kortholt, A]] | [[Category: Kortholt, A]] | ||
| + | [[Category: Messias, A C]] | ||
[[Category: Sattler, M]] | [[Category: Sattler, M]] | ||
[[Category: Wittinghofer, A]] | [[Category: Wittinghofer, A]] | ||
| - | [[Category: | + | [[Category: Inhibitor]] |
| + | [[Category: Kinase]] | ||
| + | [[Category: Lrrk2]] | ||
| + | [[Category: Roco-protein]] | ||
| + | [[Category: Transferase]] | ||
Revision as of 12:49, 6 May 2015
Humanized Roco4 bound to LRRK2-In1
| |||||||||||
